3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
5
Breast Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Glioblastoma
2
Urinary Bladder Neoplasms
1
Stroke
1
Stress Disorders, Post-Traumatic
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Myelodysplastic Syndromes
1
Motor Activity
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Localized Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Palliative Care
×
90 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled